Online citations, reference lists, and bibliographies.
← Back to Search

Efficacy Of Phase 1 Trials In Malignant Pleural Mesothelioma: Description Of A Series Of Patients At A Single Institution.

J. Raphael, G. Le Teuff, A. Hollebecque, C. Massard, R. Bahleda, J. Margery, B. Besse, J. Soria, D. Planchard
Published 2014 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
BACKGROUND Malignant pleural mesothelioma (MPM) is a locally aggressive disease with a poor prognosis. After failure of first line platinum-based chemotherapy, there is no widely approved salvage regimen. New strategies for treatment are needed and phase 1 trials appear as a rationale alternative. MATERIALS AND METHODS MPM patients were enrolled in 20 different phase 1 trials between March 2005 and January 2012, and their data analyzed retrospectively. The primary endpoint was response rate and secondary endpoints were toxicity profile, overall survival (OS) and progression free survival (PFS). OS and PFS were estimated using Kaplan-Meier and their association with baseline characteristics was investigated through a log-rank test. The drugs described were divided into 5 groups based on their mechanism of action. RESULTS Forty-five patients were analyzed with a median follow up of 20.5 months. The best tumor response was as follows: 4% of patients had a RECIST partial response, 60% had stable disease, 24% had progressive disease and 11% were not evaluable. Grade ≥3 toxicities were observed in 19 (42%) patients. Median OS and PFS were estimated to 6 months (95% CI=[4.2-10.5]) and 2 months (95% CI=[1.3-2.7]), respectively. The cellular motility inhibitors group appeared as the most promising class to be developed in a phase 2 setting. CONCLUSION Including MPM patients in phase I trials beyond first line of treatment can result in modest clinical benefits with an acceptable toxicity profile. Several molecular pathways involved in MPM have been identified and further novel biologic therapies need to be tested.
This paper references
10.1007/978-1-4757-3656-4
AJCC Cancer Staging Manual
M. B. Amin (2002)
10.1016/j.lungcan.2010.12.004
Retreatment with pemetrexed-based chemotherapy in patients with malignant pleural mesothelioma.
G. Ceresoli (2011)
10.1016/j.lungcan.2013.11.011
Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma.
P. Zucali (2014)
10.1056/NEJMoa0900212
Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.
P. Fong (2009)
10.1200/JCO.2011.39.6671
Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis.
Kevin Hollevoet (2012)
10.1200/JCO.2005.14.167
Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer.
W. Kelly (2005)
10.1016/J.HOC.2005.09.008
Antiangiogenic therapies for mesothelioma.
J. Dowell (2005)
10.1200/JCO.2008.26.15_SUPPL.8063
Phase II study of sunitinib as second-line therapy in malignant pleural mesothelioma (MPM)
A. Nowak (2008)
10.3816/CLC.2006.N.003
Potential role of histone deacetylase inhibitors in mesothelioma: clinical experience with suberoylanilide hydroxamic acid.
L. Krug (2006)
10.1016/S0959-8049(11)70098-3
VANTAGE 014: Vorinostat (V) in Patients With Advanced Malignant Pleural Mesothelioma (MPM) who Have Failed Prior Pemetrexed and Either Cisplatin or Carboplatin Therapy: A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial
L. Krug (2011)
10.1158/1078-0432.CCR-13-2098
Tumor Growth Rate Is an Early Indicator of Antitumor Drug Activity in Phase I Clinical Trials
C. Ferté (2013)
10.1056/NEJMoa0905360
Inhibition of the hedgehog pathway in advanced basal-cell carcinoma.
D. V. Von Hoff (2009)
10.1007/s00280-011-1655-3
Review on clinical trials of targeted treatments in malignant mesothelioma
J. N. Jakobsen (2011)
10.1158/1535-7163.MCT-07-0052
Inhibition of c-Src expression and activation in malignant pleural mesothelioma tissues leads to apoptosis, cell cycle arrest, and decreased migration and invasion
A. Tsao (2007)
10.1016/S1470-2045(11)70149-8
Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study
T. Treasure (2011)
10.2217/fon.09.7
Malignant pleural mesothelioma.
R. Stahel (2009)
10.1200/JCO.2011.41.5869
Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma.
H. Kindler (2012)
10.1200/JCO.2006.24.18_SUPPL.7081
Vatalanib (V) for patients with previously untreated advanced malignant mesothelioma (MM): A phase II study by the Cancer and Leukemia Group B (CALGB 30107).
T. Jahan (2006)
10.1002/cncr.23337
Gemcitabine and vinorelbine in pemetrexed‐pretreated patients with malignant pleural mesothelioma
P. Zucali (2008)
10.1016/j.lungcan.2014.03.006
Vinorelbine and gemcitabine as second- or third-line therapy for malignant pleural mesothelioma.
M. Zauderer (2014)
10.1158/1078-0432.CCR-04-1940
Gefitinib in Patients with Malignant Mesothelioma: A Phase II Study by the Cancer and Leukemia Group B
R. Govindan (2005)
10.1055/S-0031-1298905
Das maligne Mesotheliom der Pleura
T. Ploenes (2012)
10.1093/annonc/mdq173
Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
R. Stahel (2010)
10.1158/1078-0432.CCR-07-0536
Bortezomib Inhibits Nuclear Factor-κB–Dependent Survival and Has Potent In vivo Activity in Mesothelioma
A. Sartore-Bianchi (2007)
10.1200/JCO.20005.14.589
Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada.
J. Van Meerbeeck (2005)
10.1002/(SICI)1097-0142(19990615)85:12<2577::AID-CNCR13>3.3.CO;2-J
A Phase II study of gemcitabine in patients with malignant pleural mesothelioma. European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group.
J. Van Meerbeeck (1999)
10.1200/JCO.2008.19.8523
Malignant pleural mesothelioma.
A. Tsao (2009)
10.1002/(SICI)1097-0142(19990615)85:12<2577::AID-CNCR13>3.0.CO;2-S
A phase II study of gemcitabine in patients with malignant pleural mesothelioma
J. van Meerbeeck (1999)
10.1007/s00280-007-0500-1
Preclinical studies of the proteasome inhibitor bortezomib in malignant pleural mesothelioma
G. Gordon (2007)
10.1038/bjc.2013.368
Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma
G. Ceresoli (2013)
10.2486/INDHEALTH.45.379
Malignant mesothelioma: global incidence and relationship with asbestos.
C. Bianchi (2007)
10.1200/JCO.2008.20.9288
Predictors of competing mortality in advanced head and neck cancer.
L. Mell (2010)
10.2217/fon.12.14
Systemic treatment of malignant pleural mesothelioma.
F. Grosso (2012)
10.1007/s00280-006-0243-4
Negative results of an Italian Group for Mesothelioma (G.I.Me.) pilot study of single-agent imatinib mesylate in malignant pleural mesothelioma
C. Porta (2006)
10.1016/J.LUNGCAN.2005.04.010
Limited efficacy of imatinib mesylate in malignant mesothelioma: a phase II trial.
A. Mathy (2005)
10.1093/ANNONC/MDH059
Modified RECIST criteria for assessment of response in malignant pleural mesothelioma.
M. Byrne (2004)
10.1016/S0169-5002(00)00166-5
Gemcitabine for malignant mesothelioma: A phase II trial by the Cancer and Leukemia Group B.
H. Kindler (2001)
10.1200/JCO.2006.09.7634
Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study.
L. Garland (2007)
10.1007/s13665-012-0010-4
Emerging therapies for malignant pleural mesothelioma
J. Quispel-Janssen (2012)
10.1024/0040-5930/A000306
Diagnostik und Therapie des malignen Pleuramesothelioms - von der Palliationzur kurativen Intention
Opitz (2012)
10.1016/S0169-5002(05)80896-7
P-403 Vatalanib in patients with previously untreated advanced malignant mesothelioma (MM): Preliminary analysis of a phase II study by the Cancer and Leukemia Group B (CALGB 30107)
T. Jahan (2005)
10.1016/j.ctrv.2009.09.003
Second-line treatment for malignant pleural mesothelioma.
G. Ceresoli (2010)
10.1016/j.lungcan.2008.04.001
The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma.
J. Stebbing (2009)
10.1158/1538-7445.AM2014-CT240
Abstract CT240: Molecular screening for cancer treatment optimization (MOSCATO 01): a prospective molecular triage trial; Interim analysis of 420 patients
C. Ferté (2014)
10.1159/000087376
Serum PDGF-AB in Pleural Mesothelioma
R. Filiberti (2005)
10.1016/S0046-8177(98)90066-1
Paraffin section detection of the c-kit gene product (CD117) in human tissues: value in the diagnosis of mast cell disorders.
D. Arber (1998)
10.1016/j.lungcan.2011.08.011
Second-line chemotherapy in malignant pleural mesothelioma: results of a retrospective multicenter survey.
P. Zucali (2012)
10.1200/JCO.2003.11.136
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
N. Vogelzang (2003)
10.1016/S1470-2045(13)70125-6
Thalidomide versus active supportive care for maintenance in patients with malignant mesothelioma after first-line chemotherapy (NVALT 5): an open-label, multicentre, randomised phase 3 study.
W. Buikhuisen (2013)
10.1016/J.LUNGCAN.2005.10.016
EGFR overexpression in malignant pleural mesothelioma. An immunohistochemical and molecular study with clinico-pathological correlations.
A. Destro (2006)
10.1159/000339259
Malignant Pleural Mesothelioma: From the Bench to the Bedside
P. Astoul (2012)
10.1016/S1470-2045(12)70344-3
Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study.
D. Camidge (2012)
10.1136/oem.2005.023200
The French National Mesothelioma Surveillance Program
M. Goldberg (2006)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar